サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1782823

肝転移治療の世界市場

Liver Metastases Treatment

出版日
ページ情報
英文 370 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.26円
肝転移治療の世界市場
出版日: 2025年08月04日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 370 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

肝転移治療の世界市場は2030年までに47億米ドルに到達

2024年に34億米ドルと推定される肝転移治療の世界市場は、2024～2030年の分析期間においてCAGR 5.6%で成長し、2030年には47億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである化学療法は、CAGR 6.0％を記録し、分析期間終了までに26億米ドルに達すると予測されます。標的療法分野の成長率は、分析期間中CAGR 5.0％と推定されます。

米国市場は9億2,460万米ドルと推定、中国はCAGR 9.0％で成長予測

米国の肝転移治療市場は、2024年に9億2,460万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGR 9.0％を牽引し、2030年には予測市場規模9億5,370万米ドルに達すると予測されます。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.7%と5.6%と予測されています。欧州では、ドイツがCAGR 3.7%で成長すると予測されています。

世界の肝転移治療市場- 主要動向と促進要因まとめ

肝転移に対する最も効果的な治療法とは？

肝転移は、他の原発性がん部位から肝臓に転移する二次性腫瘍であり、複雑な治療上の課題となっています。治療法は腫瘍の大きさ、位置、患者の全身状態によって異なります。伝統的には、転移が限定的で肝機能が良好な患者には外科的切除がゴールドスタンダードでした。肝切除は効果的ではあるが、転移が多巣性であるため、実行可能な患者はごく一部に限られます。手術が選択できない症例では、ラジオ波焼灼療法（RFA）やマイクロ波焼灼療法（MWA）のような代替アプローチがますます使用されるようになってきており、小さな腫瘍を熱破壊で標的にする低侵襲の解決策を提供しています。さらに、経動脈的化学塞栓療法（TACE）や経動脈的放射線塞栓療法（TARE）は、全身毒性を最小限に抑えながら、高用量の局所化学療法や放射線療法を肝臓に直接行うことで、特に手術不能な腫瘍を有する患者に対して支持を得ています。免疫療法は、肝転移に対してはまだ初期段階であるが、ペムブロリズマブやニボルマブのようなチェックポイント阻害薬が一部の患者で生存率を改善し、有望視されています。全身治療、特にモノクローナル抗体やチロシンキナーゼ阻害剤のような標的治療は、がん細胞の増殖に不可欠な分子経路を遮断することで治療に革命をもたらしました。さらに、定位放射線治療（SBRT）は、特に乏転移性の患者において、外科手術以外の有効な選択肢として浮上してきました。遺伝子プロファイリングを活用した個別化医療は、ますます治療選択を形作るようになってきており、腫瘍医は、万能のアプローチに頼るのではなく、腫瘍生物学に基づいて治療法を調整できるようになってきています。化学療法、放射線療法、分子標的治療薬など複数の治療法を併用する併用療法の進化は、特に大腸がん肝転移（CRLM）の無増悪生存率を著しく向上させています。

精密医療の進歩は肝転移管理をどのように変えているのか？

プレシジョン・メディシンは、分子診断、予測分析、標的治療を統合することによって、肝転移の治療状況を大きく変えてきました。血液サンプル中の循環腫瘍DNA（ctDNA）を検出するリキッドバイオプシー技術の出現は、早期発見とリアルタイムの治療モニタリングに革命をもたらしました。リキッドバイオプシーは、腫瘍の進化を非侵襲的に追跡することを可能にし、治療戦略のタイムリーな調整を促進し、耐性メカニズムの早期同定を可能にします。腫瘍の分子プロファイリングは、大腸がん転移に対するKRASおよびBRAF阻害剤、乳がん肝転移に対するHER2標的治療など、個別化治療の開発につながりました。人工知能（AI）と機械学習アルゴリズムは、膨大なデータセットを分析して特定の治療法に対する個々の反応を予測することで、治療戦略をさらに洗練させ、腫瘍学的意思決定における試行錯誤のアプローチを最小限に抑えています。さらに、AIを活用した画像技術は腫瘍の可視化と治療計画を強化し、より正確な放射線治療やインターベンショナル腫瘍学的治療を可能にしています。もうひとつの重要なブレークスルーは、画像診断薬と治療薬を組み合わせて転移細胞に高度な標的攻撃を行うセラノスティクスの台頭です。ルテチウム-177とイットリウム-90をベースとした放射性同位元素療法は、神経内分泌や大腸の肝転移の治療においてその有効性が認められつつあります。さらに、オルガノイドを用いた調査（患者由来の腫瘍細胞を実験室環境で培養し、薬剤の有効性を検証する）が統合されることで、精密腫瘍学がさらに洗練される可能性があります。マイクロサテライト不安定性（MSI）の状態や腫瘍変異負荷（TMB）のような予測バイオマーカーの役割の増大も、免疫療法の適用を形成する上で極めて重要な役割を果たしており、最も反応性の高い患者集団にのみ、高価だが効果の高い治療が受けられるようにしています。これらの技術革新は、生存成績の改善と治療関連毒性の軽減を約束する、高度に個別化されたデータ主導の治療戦略へのシフトを強調するものです。

低侵襲治療は肝転移治療の未来か？

肝転移治療における低侵襲治療へのシフトは、腫瘍学における最も決定的な動向の一つです。従来の外科的切除術は効果的ではあるが、大きなリスク、より長い入院期間、より高い合併症率を伴うため、より低侵襲な選択肢への需要が高まっています。インターベンショナル・ラジオロジーは、経皮的アブレーション技術（ラジオ波焼灼術（RFA）やマイクロ波焼灼術（MWA））のような画期的な治療法への道を開いた。クライオアブレーションは、あまり広く用いられていないが、腫瘍細胞を効果的に破壊しながら周囲組織の完全性を保つことができるため、普及しつつあります。腹腔鏡手術やロボット支援手術の普及は、精度の向上、切開創の縮小、回復時間の短縮を可能にし、この分野にさらなる変革をもたらしました。化学塞栓療法（TACE）や放射線塞栓療法（TARE）などの経動脈的治療は、切除不能な肝転移を有する患者、特に大腸がんや肝細胞がんの症例に対する標準的な治療法となっています。ロボット肝切除術を含むロボット支援手術の普及により、外科医は複雑な手技を器用にこなし、患者の外傷を最小限に抑えることができるようになりました。ナノテクノロジーに基づくドラッグデリバリーシステムもまた、腫瘍に化学療法剤を直接投与する手段を提供し、特異性を向上させることで、全身的な副作用を軽減することができるようになりつつあります。さらに、高密度焦点式超音波（HIFU）は、切開や麻酔を必要とせずに音波を利用してがん組織を破壊する、有望な非侵襲的治療法として台頭してきています。ヘルスケアシステムが患者中心の治療へとシフトし続ける中、外来ベースの低侵襲治療への需要が高まり、世界のヘルスケア環境における肝転移の管理方法にパラダイムシフトをもたらすと考えられています。

世界の肝転移治療市場の成長を牽引しているのは？

肝転移治療市場の成長は、標的治療の進歩、低侵襲治療の採用増加、世界のがん負担の増加など、いくつかの要因によって牽引されています。遺伝子プロファイリングやバイオマーカー主導型治療におけるブレークスルーに後押しされた精密医療へのシフトは、治療の展望を広げ、優れた臨床転帰をもたらす個別化治療戦略を可能にしています。ロボット支援手術やAIを活用した画像診断など、インターベンショナル・ラジオロジーにおける技術革新は治療手順を合理化し、より効果的で利用しやすいものにしています。肝転移の主な原因となる大腸がん、乳がん、肺がんの有病率の増加は、新たな治療オプションに対する需要を押し上げています。さらに、腫瘍学の研究開発、特に免疫療法や併用療法への投資が増加していることも、市場拡大を加速させています。外来治療や低侵襲治療に対する消費者の嗜好の高まりは、ラジオ波焼灼療法（RFA）、経動脈的化学塞栓療法（TACE）、定位体放射線治療（SBRT）などの技術の採用増加につながり、市場の成長をさらに促進しています。リキッドバイオプシーとAI主導型診断の導入は早期発見を可能にし、患者の層別化と治療成績の改善につながります。さらに、バイオ医薬品との提携や戦略的パートナーシップの急増がイノベーションを促進し、新規肝転移治療薬の商業化を後押ししています。新興国におけるがん研究や先進治療へのアクセスを支援する政府の取り組みは、市場の拡大に重要な役割を果たしています。費用対効果と患者のQOLが優先される価値ベースのヘルスケアモデルへのシフトは、非侵襲的な標的治療への需要をさらに促進しています。最後に、次世代免疫療法や遺伝子編集技術を含む実験的治療の臨床試験に対する認識と採用の高まりは、肝転移治療がより効果的であるだけでなく、個々の患者のニーズにますます適合する未来を示唆しています。

セグメント

治療タイプ（化学療法、標的療法、免疫療法）、原発性がん（大腸がん、乳がん）、流通チャネル（病院薬局、専門薬局）

調査対象企業の例

  • 89bio, Inc.
  • Akero Therapeutics
  • AstraZeneca
  • Bayer AG
  • Biocompatibles UK Ltd.
  • Bristol-Myers Squibb Company
  • Cadila Pharmaceuticals Ltd.
  • Delcath Systems, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genentech（a member of Roche Group）
  • Madrigal Pharmaceuticals
  • Merck & Co., Inc.
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Plus Therapeutics, Inc.
  • Regeneron Pharmaceuticals
  • SillaJen, Inc.
  • Sirtex Medical Limited

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMをクエリする代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP31872

Global Liver Metastases Treatment Market to Reach US$4.7 Billion by 2030

The global market for Liver Metastases Treatment estimated at US$3.4 Billion in the year 2024, is expected to reach US$4.7 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$2.6 Billion by the end of the analysis period. Growth in the Targeted Therapy segment is estimated at 5.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$924.6 Million While China is Forecast to Grow at 9.0% CAGR

The Liver Metastases Treatment market in the U.S. is estimated at US$924.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$953.7 Million by the year 2030 trailing a CAGR of 9.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 5.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Global Liver Metastases Treatment Market - Key Trends & Drivers Summarized

What Are the Most Effective Treatment Modalities for Liver Metastases?

Liver metastases, secondary tumors that spread to the liver from other primary cancer sites, present a complex therapeutic challenge. Treatment modalities vary depending on tumor size, location, and the patient’s overall health condition. Traditionally, surgical resection has been the gold standard for patients with limited metastases and good liver function. Hepatectomy, though effective, is only feasible for a small percentage of patients due to the multifocal nature of metastases. In cases where surgery is not an option, alternative approaches like radiofrequency ablation (RFA) and microwave ablation (MWA) are increasingly used, offering a minimally invasive solution to target small tumors with thermal destruction. Additionally, transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) have gained traction, particularly for patients with inoperable tumors, by delivering high-dose localized chemotherapy or radiation directly to the liver while minimizing systemic toxicity. Immunotherapy, though still in its early stages for liver metastases, has shown promise, with checkpoint inhibitors like pembrolizumab and nivolumab improving survival rates in select patients. Systemic therapies, particularly targeted treatments like monoclonal antibodies and tyrosine kinase inhibitors, have revolutionized treatment by blocking molecular pathways essential for cancer cell proliferation. Moreover, stereotactic body radiotherapy (SBRT) has emerged as a viable non-surgical option, particularly in patients with oligometastatic disease. Personalized medicine, leveraging genetic profiling, is increasingly shaping treatment selection, allowing oncologists to tailor therapies based on tumor biology rather than relying on a one-size-fits-all approach. The evolution of combination therapies-where multiple modalities such as chemotherapy, radiation, and targeted agents are used in tandem-has significantly improved progression-free survival rates, particularly for colorectal cancer liver metastases (CRLM).

How Are Advancements in Precision Medicine Transforming Liver Metastases Management?

Precision medicine has significantly altered the treatment landscape for liver metastases by integrating molecular diagnostics, predictive analytics, and targeted therapies. The advent of liquid biopsy techniques, which detect circulating tumor DNA (ctDNA) in blood samples, has revolutionized early detection and real-time treatment monitoring. Liquid biopsies allow for non-invasive tracking of tumor evolution, facilitating timely adjustments to therapeutic strategies and enabling the early identification of resistance mechanisms. Molecular profiling of tumors has led to the development of personalized therapies, such as KRAS and BRAF inhibitors for colorectal cancer metastases and HER2-targeted treatments for breast cancer liver metastases. Artificial intelligence (AI) and machine learning algorithms are further refining treatment strategies by analyzing vast datasets to predict individual responses to specific therapies, minimizing trial-and-error approaches in oncologic decision-making. Additionally, AI-driven imaging technologies are enhancing tumor visualization and treatment planning, allowing for more precise radiation and interventional oncology procedures. Another significant breakthrough is the rise of theranostics, where diagnostic imaging agents and therapeutic drugs are combined to deliver a highly targeted attack on metastatic cells. Lutetium-177 and Yttrium-90-based radioisotope therapies are gaining recognition for their efficacy in treating neuroendocrine and colorectal liver metastases. Furthermore, the integration of organoid-based research-where patient-derived tumor cells are grown in lab environments to test drug efficacy-holds the potential to refine precision oncology further. The increasing role of predictive biomarkers, such as microsatellite instability (MSI) status and tumor mutational burden (TMB), has also played a pivotal role in shaping immunotherapy applications, ensuring that only the most responsive patient populations receive these costly but highly effective treatments. These innovations collectively underscore a shift towards highly individualized, data-driven treatment strategies that promise improved survival outcomes and reduced treatment-related toxicity.

Is Minimally Invasive Therapy the Future of Liver Metastases Treatment?

The shift toward minimally invasive procedures in liver metastases treatment has been one of the most defining trends in oncology. Conventional surgical resection, though effective, comes with significant risks, longer hospital stays, and higher complication rates, leading to an increased demand for less invasive options. Interventional radiology has paved the way for breakthroughs like percutaneous ablation techniques-radiofrequency ablation (RFA) and microwave ablation (MWA)-which have demonstrated comparable survival benefits for patients with limited metastases while reducing procedure-related morbidity. Cryoablation, though less widely used, is gaining traction due to its ability to preserve surrounding tissue integrity while effectively destroying tumor cells. The widespread adoption of laparoscopic and robotic-assisted surgery has further revolutionized the field by allowing for enhanced precision, smaller incisions, and quicker recovery times. Transarterial therapies, such as chemoembolization (TACE) and radioembolization (TARE), have become standard-of-care approaches for patients with unresectable liver metastases, particularly in colorectal and hepatocellular carcinoma cases. The growing use of robotic-assisted interventions, including robotic liver resections, has enabled surgeons to perform complex procedures with enhanced dexterity and minimal trauma to the patient. Nanotechnology-based drug delivery systems are also on the horizon, providing a means to administer chemotherapeutic agents directly to tumors with improved specificity, reducing systemic side effects. Moreover, high-intensity focused ultrasound (HIFU) is emerging as a promising non-invasive modality, leveraging sound waves to destroy cancerous tissue without the need for incisions or anesthesia. As healthcare systems continue to shift towards patient-centric care, the demand for outpatient-based, minimally invasive treatments is set to rise, offering a paradigm shift in how liver metastases are managed across global healthcare settings.

What Is Driving Growth in the Global Liver Metastases Treatment Market?

The growth in the liver metastases treatment market is driven by several factors, including advancements in targeted therapy, the increasing adoption of minimally invasive treatments, and a rising global cancer burden. The shift towards precision medicine, fueled by breakthroughs in genetic profiling and biomarker-driven therapies, has expanded the treatment landscape, allowing for personalized therapeutic strategies that yield superior clinical outcomes. Technological innovations in interventional radiology, such as robotic-assisted surgery and AI-powered imaging, are streamlining treatment procedures, making them more effective and accessible. The increasing prevalence of colorectal, breast, and lung cancers-primary contributors to liver metastases-is pushing the demand for novel therapeutic options. Moreover, the rising investment in oncology research and development, particularly in immunotherapy and combination therapies, is accelerating market expansion. Growing consumer preference for outpatient and minimally invasive procedures has led to increased adoption of techniques like radiofrequency ablation (RFA), transarterial chemoembolization (TACE), and stereotactic body radiotherapy (SBRT), further propelling market growth. The introduction of liquid biopsies and AI-driven diagnostics is enabling early detection, leading to improved patient stratification and treatment outcomes. Additionally, the surge in biopharmaceutical collaborations and strategic partnerships is fostering innovation, driving the commercialization of novel liver metastases therapies. Government initiatives supporting cancer research and access to advanced treatments in emerging economies are playing a crucial role in expanding market reach. The shift towards value-based healthcare models, where cost-effectiveness and patient quality of life are prioritized, has further fueled the demand for non-invasive and targeted therapies. Lastly, the growing awareness and adoption of clinical trials for experimental treatments, including next-generation immunotherapies and gene editing technologies, signal a future where liver metastases treatment is not only more effective but also increasingly tailored to individual patient needs.

SCOPE OF STUDY:

The report analyzes the Liver Metastases Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy); Primary Cancer (Colorectal Cancer, Breast Cancer); Distribution Channel (Hospital Pharmacies, Specialty Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • 89bio, Inc.
  • Akero Therapeutics
  • AstraZeneca
  • Bayer AG
  • Biocompatibles UK Ltd.
  • Bristol-Myers Squibb Company
  • Cadila Pharmaceuticals Ltd.
  • Delcath Systems, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genentech (a member of Roche Group)
  • Madrigal Pharmaceuticals
  • Merck & Co., Inc.
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Plus Therapeutics, Inc.
  • Regeneron Pharmaceuticals
  • SillaJen, Inc.
  • Sirtex Medical Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Liver Metastases Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Secondary Liver Tumors Throws the Spotlight on Advancements in Liver Metastases Treatment
    • Increasing Use of Precision Oncology and Genomic Profiling Drives Adoption of Targeted Therapy Approaches
    • OEM Innovation in Liver-Directed Therapies Such as TARE and TACE Strengthens Localized Treatment Modalities
    • Expansion of Immunotherapy Combinations Spurs New Pathways for Metastatic Liver Cancer Management
    • Growing Integration of Artificial Intelligence in Imaging and Planning Drives Surgical and Radiological Precision
    • Regulatory Approvals of New Systemic Therapies Accelerate Access to Multiline Treatment Protocols
    • OEM Development of Minimally Invasive Ablation Technologies Enhances Patient Recovery and Hospital Efficiency
    • Rising Use of Hepatic Artery Infusion Chemotherapy (HAIC) in Colorectal Liver Metastases Propels Procedural Uptake
    • Increased Adoption of Multidisciplinary Care Models Strengthens Coordination Across Oncology Specialties
    • OEM Partnerships With Academic Institutions Drive Development of Next-Generation Liver Metastases Treatment Protocols
    • Expansion of Transplant Eligibility Criteria for Selected Liver Metastases Patients Spurs Surgical Innovation
    • Surge in Biomarker-Driven Clinical Trials Generates New Therapeutic Targets in Hepatic Metastatic Cancers
    • OEM Emphasis on Personalized Dosimetry in Radiation Therapy Enhances Tumor Control and Reduces Toxicity
    • Growing Patient Awareness and Earlier Diagnosis Increase Candidate Pools for Curative Liver Interventions
    • Emergence of Radiomics and Predictive Modeling Supports Risk Stratification and Treatment Customization
    • Expansion of Proton Therapy and Stereotactic Techniques Strengthens Non-Invasive Treatment Options
    • Rising Need for Palliative Interventions in Advanced-Stage Patients Spurs Innovation in Comfort-Focused Procedures
    • OEM Investment in Drug-Eluting Beads and Precision Embolic Platforms Enhances Drug Delivery Efficiency
    • Globalization of Clinical Trial Participation Expands Market Access to Novel Liver Metastases Therapies
    • Focus on Real-World Evidence and Post-Market Surveillance Reinforces Long-Term Safety and Efficacy Validation
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Liver Metastases Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Liver Metastases Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Liver Metastases Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Liver Metastases Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Specialty Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Specialty Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Specialty Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • JAPAN
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • CHINA
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • EUROPE
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Liver Metastases Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Liver Metastases Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Liver Metastases Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • FRANCE
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: France 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 77: France Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • GERMANY
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 83: Germany Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Germany Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Germany 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Italy Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Italy 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 101: UK Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UK Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: UK 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 110: Spain Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Spain Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Spain 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Spain 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 119: Russia Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Russia Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Russia 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Russia 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Europe Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Europe 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Liver Metastases Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 138: Asia-Pacific Historic Review for Liver Metastases Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Asia-Pacific 15-Year Perspective for Liver Metastases Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 149: Australia Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Australia Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Australia 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Australia 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • INDIA
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 158: India Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: India Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: India 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 161: India Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: India 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 167: South Korea Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: South Korea Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: South Korea 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: South Korea 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 176: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Rest of Asia-Pacific Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Rest of Asia-Pacific 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 185: Latin America Recent Past, Current & Future Analysis for Liver Metastases Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 186: Latin America Historic Review for Liver Metastases Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Latin America 15-Year Perspective for Liver Metastases Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Latin America 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 197: Argentina Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Argentina Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Argentina 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Argentina 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 206: Brazil Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Brazil Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Brazil 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Brazil 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 215: Mexico Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Mexico Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Mexico 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Mexico 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 224: Rest of Latin America Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Rest of Latin America Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: Rest of Latin America 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 233: Middle East Recent Past, Current & Future Analysis for Liver Metastases Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 234: Middle East Historic Review for Liver Metastases Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: Middle East 15-Year Perspective for Liver Metastases Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: Middle East 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 245: Iran Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Iran Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Iran 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Iran 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 254: Israel Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Israel Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Israel 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Israel 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 263: Saudi Arabia Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Saudi Arabia Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Saudi Arabia 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 272: UAE Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: UAE Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: UAE 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: UAE 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 281: Rest of Middle East Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Rest of Middle East Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: Rest of Middle East 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • AFRICA
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 290: Africa Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Africa Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: Africa 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: Africa 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030

IV. COMPETITION